Skip to main content
Top
Published in: Current Heart Failure Reports 4/2013

01-12-2013 | Epidemiology of Heart Failure (J Butler, Section Editor)

Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials

Authors: Abhinav Sharma, Justin A. Ezekowitz

Published in: Current Heart Failure Reports | Issue 4/2013

Login to get access

Abstract

Acute and chronic heart failure results in significant morbidity and mortality to patients and is a major concern for the healthcare systems. Various randomized controlled trials have demonstrated an improvement in morbidity and mortality for patients with heart failure. However, the findings of these trials are often applicable to a limited population. Several large-scale registries are now shedding insight as to the treatment, outcomes, and follow-up of patients in a real-life clinical setting. The objective of this review is to examine some of the heart failure therapies, such as cardiac resynchronization therapy, implantable cardioverter defibrillators and medications, in the context of randomized trials versus clinical registries. This review will also identify how registries are improving patient outcomes and how they are uncovering differences and gaps in treatment in non-randomized trial settings.
Literature
1.
go back to reference McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on acute and chronic heart failure. CJCA. 2013;29(2):168–81. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on acute and chronic heart failure. CJCA. 2013;29(2):168–81.
2.
go back to reference America HFSO. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):475–539.CrossRef America HFSO. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):475–539.CrossRef
3.
go back to reference McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef
4.
go back to reference Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.PubMedCrossRef Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.PubMedCrossRef
5.
go back to reference Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, et al. Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. J Clin Epidemiol. 2013;66(3):286–95.PubMedCrossRef Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, et al. Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. J Clin Epidemiol. 2013;66(3):286–95.PubMedCrossRef
6.
go back to reference Kulkarni AV, Busse JW, Shams I. Characteristics associated with citation rates of the medical literature. PLoS One. 2007;2:e403.PubMedCrossRef Kulkarni AV, Busse JW, Shams I. Characteristics associated with citation rates of the medical literature. PLoS One. 2007;2:e403.PubMedCrossRef
7.
go back to reference Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am J Manag Care. 2004;10(7 Pt 2):487–92.PubMed Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am J Manag Care. 2004;10(7 Pt 2):487–92.PubMed
8.
go back to reference Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother. 2012;46(2):282–9.PubMedCrossRef Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother. 2012;46(2):282–9.PubMedCrossRef
9.
go back to reference Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. JMCP. 2012;87(6):555–60. Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. JMCP. 2012;87(6):555–60.
10.
go back to reference Hong Y, LaBresh KA. Overview of the American Heart Association “Get With the Guidelines” programs: coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol. 2006;5:179–86.PubMedCrossRef Hong Y, LaBresh KA. Overview of the American Heart Association “Get With the Guidelines” programs: coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol. 2006;5:179–86.PubMedCrossRef
11.
go back to reference Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel M, Smith EE, et al. Get with the guidelines: stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or TIA. Circulation. 2009;119:107–15.PubMedCrossRef Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel M, Smith EE, et al. Get with the guidelines: stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or TIA. Circulation. 2009;119:107–15.PubMedCrossRef
12.
go back to reference LaBresh KA, Fonarow GC, Smith Jr SC, Bonow RO, Smaha LC, Tyler PA, et al. Improved treatment of hospitalized coronary artery disease patients with the Get With the Guidelines Program. Crit Pathw Cardiol. 2007;6:98–105.PubMedCrossRef LaBresh KA, Fonarow GC, Smith Jr SC, Bonow RO, Smaha LC, Tyler PA, et al. Improved treatment of hospitalized coronary artery disease patients with the Get With the Guidelines Program. Crit Pathw Cardiol. 2007;6:98–105.PubMedCrossRef
13.
go back to reference • Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get with the guidelines program participation, process of care, and outcome for Medicare Patients Hospitalized With Heart Failure. Circ Cardiovasc Qual Outcomes. 2012;5(1):37–43. This reference highlights the feasibility of creating a large-scale registry that promotes adherence to clinical guidelines.PubMedCrossRef • Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get with the guidelines program participation, process of care, and outcome for Medicare Patients Hospitalized With Heart Failure. Circ Cardiovasc Qual Outcomes. 2012;5(1):37–43. This reference highlights the feasibility of creating a large-scale registry that promotes adherence to clinical guidelines.PubMedCrossRef
14.
go back to reference Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–96.PubMedCrossRef Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–96.PubMedCrossRef
15.
go back to reference Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076–84.PubMedCrossRef Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076–84.PubMedCrossRef
16.
go back to reference Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol. 2004;20(4):417–21.PubMed Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol. 2004;20(4):417–21.PubMed
17.
go back to reference Hordijk-Trion M, Lenzen M, Wijns W, et al. EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27(6):671–8.PubMedCrossRef Hordijk-Trion M, Lenzen M, Wijns W, et al. EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27(6):671–8.PubMedCrossRef
18.
go back to reference Badano LP, DiLenarda A, Bellotti P, Albanese MC, Sinagra G, Fioretti PM. Patients with chronic heart failure encountered in daily clinical practice are different from the “typical” patient enrolled in therapeutic trials. Ital Heart J. 2003;4(2):84–91.PubMed Badano LP, DiLenarda A, Bellotti P, Albanese MC, Sinagra G, Fioretti PM. Patients with chronic heart failure encountered in daily clinical practice are different from the “typical” patient enrolled in therapeutic trials. Ital Heart J. 2003;4(2):84–91.PubMed
19.
go back to reference Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013;309(1):55–62.PubMedCrossRef Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013;309(1):55–62.PubMedCrossRef
20.
go back to reference Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002). Prophylactic implantation of a defibrillator in pa- tients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.PubMedCrossRef Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002). Prophylactic implantation of a defibrillator in pa- tients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.PubMedCrossRef
21.
go back to reference Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.PubMedCrossRef Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.PubMedCrossRef
22.
go back to reference Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C, Setoguchi S, et al. Follow-up of Patients With New Cardiovascular Implantable Electronic Devices: are experts' recommendations implemented in routine clinical practice? Circ Arrhythm Electrophysiol. 2013;6(1):108–16.PubMedCrossRef Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C, Setoguchi S, et al. Follow-up of Patients With New Cardiovascular Implantable Electronic Devices: are experts' recommendations implemented in routine clinical practice? Circ Arrhythm Electrophysiol. 2013;6(1):108–16.PubMedCrossRef
23.
go back to reference Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol. 2006;15(2):88–92.PubMedCrossRef Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol. 2006;15(2):88–92.PubMedCrossRef
24.
go back to reference • McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med. 2005;352(3):222–4. This reference provides excellent insight into the economic implications of ICDs.PubMedCrossRef • McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med. 2005;352(3):222–4. This reference provides excellent insight into the economic implications of ICDs.PubMedCrossRef
25.
go back to reference Medical Advisory Secretariat. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Ontario Health Technology Assessment Series 2005;5(14). Medical Advisory Secretariat. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Ontario Health Technology Assessment Series 2005;5(14).
26.
go back to reference Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251–62.PubMedCrossRef Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251–62.PubMedCrossRef
27.
go back to reference Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med. 2011;154(6):401–12.PubMedCrossRef Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med. 2011;154(6):401–12.PubMedCrossRef
28.
go back to reference • Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart. 2012;98(24):1828–36. This reference provides a very comprehensive analysis of the cost effectiveness of CRT. • Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart. 2012;98(24):1828–36. This reference provides a very comprehensive analysis of the cost effectiveness of CRT.
29.
go back to reference Fumagalli S, Valsecchi S, Boriani G, Gasparini M, Landolina M, Lunati M, et al. Comparison of the usefulness of cardiac resynchronization therapy in Three Age-Groups. AJC. 2011;107(10):1510–6.CrossRef Fumagalli S, Valsecchi S, Boriani G, Gasparini M, Landolina M, Lunati M, et al. Comparison of the usefulness of cardiac resynchronization therapy in Three Age-Groups. AJC. 2011;107(10):1510–6.CrossRef
30.
go back to reference Curtis AB, Yancy CW, Albert NM, Stough WG, Gheorghiade M, Heywood JT, et al. Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. Am Heart J. 2009;158(6):956–64.PubMedCrossRef Curtis AB, Yancy CW, Albert NM, Stough WG, Gheorghiade M, Heywood JT, et al. Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. Am Heart J. 2009;158(6):956–64.PubMedCrossRef
31.
go back to reference Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, et al. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol. 2013;36(4):433–43.PubMedCrossRef Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, et al. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol. 2013;36(4):433–43.PubMedCrossRef
32.
go back to reference Taubert G, Bergmeier C, Andresen H, Senges J, Potratz J. Clinical profile and management of heart failure: rural community hospital vs. metropolitan heart center. Eur J Heart Fail. 2001;3(5):611–7.PubMedCrossRef Taubert G, Bergmeier C, Andresen H, Senges J, Potratz J. Clinical profile and management of heart failure: rural community hospital vs. metropolitan heart center. Eur J Heart Fail. 2001;3(5):611–7.PubMedCrossRef
33.
go back to reference Sanborn MD, Manuel DG, Ciechanska E, Lee DS. Potential gaps in congestive heart failure management in a rural hospital. Can J Rural Med. 2005;10(3):155–61.PubMed Sanborn MD, Manuel DG, Ciechanska E, Lee DS. Potential gaps in congestive heart failure management in a rural hospital. Can J Rural Med. 2005;10(3):155–61.PubMed
34.
go back to reference Clark RA, Eckert KA, Stewart S, Phillips SM, Yallop JJ, Tonkin AM, et al. Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study. Med J Aust. 2007;186(9):441.PubMed Clark RA, Eckert KA, Stewart S, Phillips SM, Yallop JJ, Tonkin AM, et al. Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study. Med J Aust. 2007;186(9):441.PubMed
35.
go back to reference Muus KJ, Knudson A, Klug MG, Gokun J, Sarrazin M, Kaboli P. Effect of postdischarge follow-up care on re-admissions among US veterans with congestive heart failure: a rural–urban comparison. Rural Rem Health. 2010;10(2):1447. Muus KJ, Knudson A, Klug MG, Gokun J, Sarrazin M, Kaboli P. Effect of postdischarge follow-up care on re-admissions among US veterans with congestive heart failure: a rural–urban comparison. Rural Rem Health. 2010;10(2):1447.
36.
go back to reference Lenzen MJ. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26(24):2706–13.PubMedCrossRef Lenzen MJ. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26(24):2706–13.PubMedCrossRef
37.
go back to reference The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRef The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRef
38.
go back to reference The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef
39.
go back to reference Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef
40.
go back to reference Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332–7.PubMedCrossRef Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332–7.PubMedCrossRef
41.
go back to reference Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108(7):839–43.PubMedCrossRef Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108(7):839–43.PubMedCrossRef
42.
go back to reference Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93(9):1124–9.PubMedCrossRef Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93(9):1124–9.PubMedCrossRef
43.
go back to reference Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119(1):48–53.PubMedCrossRef Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119(1):48–53.PubMedCrossRef
44.
go back to reference Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(4):415–26.PubMedCrossRef Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(4):415–26.PubMedCrossRef
45.
go back to reference Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, et al. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009;15(4):159–64.PubMedCrossRef Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, et al. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009;15(4):159–64.PubMedCrossRef
46.
go back to reference Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–61.PubMedCrossRef Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–61.PubMedCrossRef
47.
go back to reference GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1231–9. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1231–9.
48.
go back to reference Lavie CJ, Mehra MR. Statins and advanced heart failure-alive but barely breathing after CORONA and GISSI-HF. Congestive Heart Fail. 2009;15(4):157–8.CrossRef Lavie CJ, Mehra MR. Statins and advanced heart failure-alive but barely breathing after CORONA and GISSI-HF. Congestive Heart Fail. 2009;15(4):157–8.CrossRef
49.
go back to reference •• Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, et al. Acute heart failureclinical perspective perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail. 2012;5(6):735–41. This excellent reference provides insight into the construction of a simultaneous RCT and registry.PubMedCrossRef •• Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, et al. Acute heart failureclinical perspective perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail. 2012;5(6):735–41. This excellent reference provides insight into the construction of a simultaneous RCT and registry.PubMedCrossRef
Metadata
Title
Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials
Authors
Abhinav Sharma
Justin A. Ezekowitz
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 4/2013
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-013-0152-x

Other articles of this Issue 4/2013

Current Heart Failure Reports 4/2013 Go to the issue

Epidemiology of Heart Failure (J Butler, Section Editor)

Heart Failure in Very Old Adults

Pathophysiology of Myocardial Failure (IS Anand and M Sarraf, Section Editors)

Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction

Prevention of Heart Failure (M St. John Sutton, Section Editor)

Changes in Renal Function in Congestive Heart Failure

Pathophysiology of Myocardial Failure (IS Anand and M Sarraf, Section Editors)

Revascularization in Heart Failure in the Post-STICH Era

Prevention of Heart Failure (M St. John Sutton, Section Editor)

Sleep Apnea, Heart Failure, and Pulmonary Hypertension

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.